simvastatin has been researched along with Cardiovascular Stroke in 217 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 26 (11.98) | 18.2507 |
| 2000's | 114 (52.53) | 29.6817 |
| 2010's | 73 (33.64) | 24.3611 |
| 2020's | 4 (1.84) | 2.80 |
| Authors | Studies |
|---|---|
| Blazing, MA; Braunwald, E; Cannon, CP; Giugliano, RP; Oyama, K; Park, JG; Sabatine, MS; Tershakovec, AM | 1 |
| Damasceno, NRT; Fonseca, FAH; Izar, MC; Lotfollahi, Z; Machado, LO; Mathias, AF; Mello, APQ; Neto, AMF; Oliveira, CLP | 1 |
| DʼAcunto, K; Sismour, B | 1 |
| Al-Rashid, F; Dykun, I; Hendricks, S; Jánosi, RA; Mahabadi, AA; Rassaf, T; Totzeck, M; Wiefhoff, D | 1 |
| Bastos, RT; Cruz, ECS; Derogis, PBMC; Dos Santos Ferreira, CE; Faccio, AT; Fonseca, FAH; Fontoura, SC; Izar, MC; Klassen, A; Lopes, AS; Neto, AMF; Picossi, CRC; Sussulini, A; Tavares, MFM | 1 |
| Alahmari, A; Almalki, ZS; Alotaibi, N; Guo, JJ; Thaibah, H | 1 |
| Chen, Y; Liu, L | 1 |
| Aquino, M; Baber, U; Barman, N; Camaj, A; Chandrasekhar, J; Claessen, B; Dangas, G; Faggioni, M; Farhan, S; Guedeney, P; Kalkman, DN; Kini, A; Kovacic, JC; Mehran, R; Moreno, P; Shah, S; Sharma, S; Sorrentino, S; Sweeny, J; Vijay, P; Vogel, B | 1 |
| Liu, F; Shu, M; Tang, M; Wu, X; Xia, P; Zhan, S | 1 |
| Agus, A; Campbell, C; Kennedy, G; McAuley, D; O'Kane, C; Perkins, GD; Phair, G; Shyamsundar, M | 1 |
| Chevion, M; Drenger, B; Grievink, H; Kuzmina, N | 1 |
| Dunna, NR; Foye, JL; Joshi, M; Maulik, N; Otani, H; Selvaraju, V; Thirunavukkarasu, M | 1 |
| Balu, S; Montouchet, C; Ruff, L | 1 |
| D'Ettorre, A; Macchia, A; Mariani, J; Romero, M; Tognoni, G | 1 |
| Kang, S; Liu, XB; Liu, Y | 1 |
| Choy, AM; Elder, DH; Lang, CC; Macdonald, TM; Majeed, A; Noman, AY; Ogston, S; Pauriah, M; Struthers, AD; Wyatt, JC | 1 |
| Buse, JB; Cohen, RM; Cushman, WC; Cutler, JA; Evans, GW; Gerstein, HC; Goff, DC; Grimm, RH; Lipkin, EW; Margolis, KL; Morgan, TM; Narayan, KM; O'Connor, PJ; Riddle, MC; Sood, A | 1 |
| Currie, CJ; Halcox, JP | 1 |
| Long, HB; Luo, KQ; Xu, BC | 1 |
| Boekholdt, SM; Fayyad, R; Hovingh, GK; Laskey, R; Pedersen, TR; Stoekenbroek, RM; Tikkanen, MJ | 1 |
| Špinar, J; Špinarová, L; Vítovec, J | 1 |
| Phongtuntakul, B; Tungsubutra, W | 1 |
| Chu, W; Duan, W; Liu, Z; Lu, Y; Qile, M; Qiu, F; Sun, F; Zhang, L; Zhang, Y; Zhao, D | 1 |
| Choi, YH; Hellmich, M; Krause, P; Kuhn, EW; Kuhr, K; Liakopoulos, OJ; Reuter, H; Thurat, M; Wahlers, T | 1 |
| Gandhi, HP; Patel, SS; Rathod, SP; Trivedi, JI; Variya, BC | 1 |
| Stiefelhagen, P | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Tershakovec, AM; White, JA; Zhou, J | 1 |
| Amirsadri, M; Hassani, A | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Dellborg, M; Giugliano, RP; Im, K; Isaza, D; Kher, U; Lokhnygina, Y; Lopez-Sendon, J; Murphy, SA; Reist, C; Tershakovec, AM; White, JA | 1 |
| Murphy, J; Wright, RS | 1 |
| Chang, YH; Chien, LN; Chuang, MT; Lin, CF; Liu, JC | 1 |
| Luteijn, JM; Morris, JK; Oppenheimer, P; Taylor, D; Wald, NJ | 1 |
| Luteijn, JM; Morris, JK; Wald, NJ | 1 |
| Chang, G; Liu, J; Liu, L; Qin, S; Sun, G; Xiao, X; Zhang, D | 1 |
| Albers, JJ; Fleg, JL; Marcovina, SM; O'Brien, KD; Slee, A | 1 |
| Anderson, ML; Blasi, PR; Dunn, J; Henrikson, NB; Lozano, P; Morrison, CC; Nguyen, M; Whitlock, EP | 1 |
| Armitage, J; Baigent, C; Blackwell, L; Blumenthal, R; Collins, R; Danesh, J; DeMets, D; Emberson, J; Evans, S; Law, M; MacMahon, S; Martin, S; Neal, B; Peto, R; Poulter, N; Preiss, D; Reith, C; Ridker, P; Roberts, I; Rodgers, A; Sandercock, P; Schulz, K; Sever, P; Simes, J; Smeeth, L; Smith, GD; Wald, N; Yusuf, S | 1 |
| Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S | 1 |
| Bangalore, S; DeMicco, DA; Fayyad, R; Kastelein, JJ; Laskey, R; Messerli, FH; Waters, DD | 1 |
| Braunwald, E; Cannon, CP; Daga, S; Dalby, AJ; Eisen, A; Goodrich, EL; Im, K; Lukas, MA; O'Donoghue, ML; Spinar, J; Steen, DL; Zhou, J | 1 |
| Blazing, MA; Bohula, EA; Brady, AJ; Braunwald, E; Cannon, CP; Giugliano, RP; He, P; Kesaniemi, YA; Mitchel, Y; Morrow, DA; Murphy, SA; Park, JG; Pedersen, TR; White, JA | 1 |
| Arbel, R; Greenberg, D | 1 |
| Li, X; Xu, B | 1 |
| Armitage, J; Bowman, L; Collins, R; Gut, I; Heath, S; Lathrop, M; Link, E; Matsuda, F; Parish, S | 1 |
| Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD | 1 |
| Basart, DC; Defesche, JC; Heeringa, J; Kastelein, JJ; Lansberg, PJ; Liem, AH; Oosterveer, DM; Sijbrands, EJ; Versmissen, J; Witteman, JC; Yazdanpanah, M | 1 |
| Jiao, ZQ; Li, YM; Liu, LM; Liu, YH; Pang, W; Zhang, M; Zhou, X | 1 |
| Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Aoyama, T; Bao, N; Iwasa, M; Kawamura, I; Kawasaki, M; Kobayashi, H; Minatoguchi, S; Nagashima, K; Nishigaki, K; Sumi, S; Takemura, G; Ushikoshi, H; Yamaki, T; Yasuda, S | 1 |
| Ridker, PM | 1 |
| Gurgel, A; Macedo, AC; Morato, TN; Munhoz, DB; Quinaglia e Silva, JC; Sever, P; Sposito, AC | 1 |
| Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ | 3 |
| Berney, R; Hack, CE; Krijnen, PA; Niessen, HW; Paulus, WJ; Pronk, A; Spreeuwenberg, M; van Dijk, A; van Milligen, FJ; Vermond, RA; Visser, FC | 1 |
| Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Strandberg, TE; Tikkanen, MJ | 1 |
| Andrade, JM; Araújo, AL; Carvalho, LS; Cintra, RM; Coelho, OR; Ono, AH; Quinaglia e Silva, JC; Sposito, AC | 1 |
| Björnberg, A; Odén, A; Welin, L; Wilhelmsen, L | 1 |
| Adameova, A; Bartekova, M; Carnicka, S; Harcarova, A; Kuzelova, M; Matejikova, J; Pancza, D; Ravingerova, T; Styk, J; Svec, P | 1 |
| Kotlarz, A; Mostowik, M; Pastuszczak, M; Undas, A; Zalewski, J; Zmudka, K | 1 |
| Delate, T; McConnell, KJ; Merenich, JA; Olson, KL | 1 |
| Bailey, KM; Balmforth, AJ; Barth, JH; Copeland, J; Efthymiou, M; Farrin, AJ; Flather, MD; Hall, AS; Jackson, BM; McCormack, T; Nixon, J; Romaine, SP; Whitehead, A | 1 |
| Dou, KF; Gao, RL; Geng, YJ; Huang, J; Li, JJ; Qian, HY; Willerson, JT; Yang, GS; Yang, YJ | 1 |
| Fan, W; Fu, X; Gu, X; Jia, X; Wei, M; Xue, L; Zhang, J | 1 |
| Goetghebeur, M; Jönsson, B; Lindgren, P; Merikle, E; Wagner, M | 1 |
| Cheng, LX; Dang, SY; Gao, W; He, CR; Sheng, FQ; Wang, CQ; Wang, W; Xu, R; Zeng, QT | 1 |
| Faergeman, O; Fayyad, R; Holdaas, H; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Bailey, KM; Balmforth, AJ; Barth, JH; Copeland, J; Efthymiou, M; Farrin, AJ; Flather, MD; Hall, AS; Jackson, BM; McCormack, T; Nixon, J; Romaine, SP; Samani, NJ; Whitehead, A | 1 |
| Bigger, JT; Buse, JB; Byington, RP; Crouse, JR; Cushman, WC; Elam, MB; Friedewald, WT; Gerstein, HC; Ginsberg, HN; Goff, DC; Grimm, RH; Ismail-Beigi, F; Leiter, LA; Linz, P; Lovato, LC; Probstfield, J; Simons-Morton, DG | 1 |
| Birnbaum, Y; Long, B; Perez-Polo, JR; Qian, J; Ye, Y | 1 |
| Bailey, KM; Balmforth, AJ; Barth, JH; Copeland, J; Efthymiou, M; Farrin, AJ; Flather, MD; Hall, AS; Jackson, BM; McCormack, T; Nixon, J; Romaine, SP; Whitehead, A; Worthy, G | 1 |
| Holme, I; Kvien, TK; Pedersen, TR; Semb, AG | 1 |
| Birnbaum, Y; Perez-Polo, JR; Ye, Y | 1 |
| Schunn, H | 1 |
| Armitage, J; Bowman, L; Bulbulia, R; Collins, R; Haynes, R; Parish, S; Peto, R; Rahimi, K; Wallendszus, K | 1 |
| Chen, T; Chen, Z; Pan, L; Xu, Y; Zhang, J; Zhao, R | 1 |
| Fan, WH; Jin, B; Li, Y; Luo, XP; Shen, W; Shi, HM | 1 |
| Fefer, P; Hod, H; Matetzky, S; Novikov, I; Savion, N; Shechter, M; Shenkman, B; Varon, D | 1 |
| Avellone, G; Campisi, D; Di Garbo, V; Guarnotta, V; Parrinello, G; Purpura, L; Scaglione, R; Torres, D | 1 |
| Chockalingam, A; Kar, S | 1 |
| Després, JP | 1 |
| Abdalla, DS; Coelho, OR; da Silva, LP; de Faria, EC; Japiassú, AV; Quinaglia e Silva, JC; Ramires, JA; Santos, SN; Soares, AA; Sposito, AC | 1 |
| Faergeman, O; Fayyad, R; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Chong, E; Poh, KK; Shen, L | 1 |
| Abe, S; Arikawa, T; Asanuma, H; Hikichi, Y; Inoue, T; Kikuchi, M; Kitakaze, M; Node, K; Sanada, S; Sohma, R; Taguchi, I; Toyoda, S | 1 |
| Akçalı, Z; Borlu, F; Namal, E; Oztekin, E; Sener, N; Ulaş, T | 1 |
| Boman, K; Devereux, RB; Egstrup, K; Gohlke-Baerwolf, C; Greve, AM; Kesäniemi, YA; Køber, L; Nienaber, C; Ray, S; Rossebø, AB; Wachtell, K; Willenheimer, R | 1 |
| Anastasiou-Nana, M; Andreadou, I; Farmakis, D; Iliodromitis, EK; Kremastinos, DT; Papalois, A; Papapetropoulos, A; Prokovas, E; Sigala, F; Spyridaki, K; Zoga, A | 1 |
| Cheng, YT; Geng, YJ; Li, XD; Wu, YL; Yang, YJ; Zhang, HT; Zhao, JL | 1 |
| Gu, B; Li, J; Li, S; Liu, M; Wang, F; Wei, M; Yu, T; Zhu, W | 1 |
| Bang, CN; Gislason, GH; Greve, AM; Køber, L; Torp-Pedersen, C; Wachtell, K | 1 |
| Bestehorn, K; Gitt, AK; Jannowitz, C; Karmann, B; Pittrow, D; Schaefer, JR; Sonntag, F; Weizel, A | 1 |
| Gumbrevičius, G; Stankevičius, E; Sveikata, A; Sveikatienė, R | 1 |
| Adameová, A; Čarnická, S; Máťuš, M; Mesárošová, L; Rajtík, T; Ravingerová, T; Švec, P; Szobi, A | 1 |
| Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD | 1 |
| Bates, K; Gaballa, MA; Goldman, S; Ruggeroli, CE | 1 |
| Jonasson, L; Linderfalk, C; Olsson, AG; Schwartz, GG | 1 |
| Ahn, C; Aronow, WS | 1 |
| Law, M; Wald, N | 1 |
| Farmer, JA | 1 |
| Kaste, M | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Aronow, WS | 2 |
| Ellis, BL; Thiemermann, C; Wayman, NS | 1 |
| George, A; Shakib, S | 1 |
| Origasa, H; Yokoyama, M | 1 |
| Krone, W | 1 |
| Ahmed, M; Griffiths, P | 1 |
| Berry, DC; Knapp, P; Raynor, DK | 1 |
| Ashitkov, T; Birnbaum, Y; Hu, ZY; Motamedi, M; Tavackoli, S; Uretsky, BF | 1 |
| Levenson, D | 1 |
| Dendorfer, A; Dominiak, P; Heep, A; Klein, HH; Richardt, G; Schutt, M; Tempel, K; Weidtmann, B; Wolfrum, S | 1 |
| Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Hur, SH; Hyun, DW; Jeong, MH; Kang, DG; Kang, JC; Kim, JH; Kim, KB; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, SY; Park, HW; Park, JC; Yun, KH | 1 |
| Jiang, D; Li, L; Luo, Y; Wen, D; Yang, J | 1 |
| Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z | 1 |
| Bhatt, DL; Karha, J | 1 |
| Cheng, X; Ge, H; Guo, Z; Li, B; Liao, YH; Liu, Y; Lu, B; Wang, M; Yang, Y; Zhang, J; Zhang, L | 1 |
| Baldwin, WM; Cameron, SJ; Greer, JJ; Lefer, DJ; Lowenstein, CJ; Matsushita, K; Morrell, CN; Talbot-Fox, K; Yamakuchi, M | 1 |
| Abildstrom, SZ; Buch, P; Friberg, J; Gislason, GH; Gustafsson, I; Køber, L; Madsen, M; Rasmussen, JN; Rasmussen, S; Stender, S; Torp-Pedersen, C | 1 |
| Cannon, CP; Ray, KK | 1 |
| Waters, DD | 1 |
| Aukrust, P; Boullier, A; Damås, JK; Green, S; Quehenberger, O; Sandberg, WJ; Smith, C; Waehre, T | 1 |
| Bendiksen, FS; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ; Tsai, J | 1 |
| Ahumada, M; Arcas, R; Arribas, JM; Gomez-Plana, J; Marín, F; Martínez, P; Oliver, C; Pascual, DA; Tornel, PL; Valdes, M | 1 |
| Scheen, AJ | 1 |
| Aarsetøy, H; Brügger-Andersen, T; Grundt, H; Hetland, Ø; Nilsen, DW | 1 |
| Bajraktari, G; Beqiri, A; Berisha, I; Elezi, S; Kastrati, S; Manaj, R; Thaqi, S | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Bybee, KA; Duchonová, R; Homolová, I; Procházková, S; Tesar, D; Veselka, J | 1 |
| Cheah, JS; Ong, HT | 1 |
| Cayley, WE | 1 |
| Ravnskov, U; Rosch, PJ; Sutter, MC | 1 |
| Mann, SJ | 1 |
| Itakura, H; Kita, T; Kono, S; Mabuchi, H; Matsuzaki, M; Matsuzawa, Y; Nakaya, N; Oikawa, S; Saito, Y; Sasaki, J; Shimamoto, K | 1 |
| Kalina, A | 1 |
| Chen, ZJ; Gao, RL; Jing, ZC; Wu, YJ; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Elrod, JW; Greer, JJ; Jones, SP; Kakkar, AK; Lefer, DJ; Watson, LJ | 1 |
| Gratsianskiĭ, NA; Masenko, VP; Smetanina, IN; Vaulin, NA | 1 |
| Cui, CJ; Gao, RL; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Ahn, Y; Cho, JG; Hong, SN; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Lee, SR; Park, HW; Park, JC; Yun, NS | 1 |
| Bauersachs, J; Fraccarollo, D; Hiss, K; Laufs, U; Ruetten, H | 1 |
| Armitage, J; Bowman, L; Collins, R; Emberson, JR; Ng, LL; Parish, S | 1 |
| Chonchol, M; Cook, T; Kjekshus, J; Lindenfeld, J; Pedersen, TR | 1 |
| Chen, KJ; Guo, Y; Shi, DZ; Yin, HJ | 1 |
| Blaimont, M; Chenot, F; de Meester, A; Descamps, OS; Marcovitch, O; Montant, PF | 1 |
| Adamus, J; Bak, A; Janczak, J; Kałka, D; Kopka, L; Korzeniowska, J; Marciniak, W; Popielewicz-Kautz, A; Sobieszczańska, M; Zawadzka-Bartczak, E | 1 |
| Bax, JJ; Davignon, J; Dunkelgrun, M; Feringa, HH; Hoeks, SE; Kastelein, JJ; Poldermans, D; Schouten, O; van Domburg, RT; Vidakovic, R; Welten, GM | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Armitage, J; Bowman, L; Bulbulia, R; Collins, R; Parish, S | 1 |
| Charbonnel, B; Dormandy, J; Erdmann, E; Massi-Benedetti, M; Wilcox, R | 1 |
| Berlion, AE; Morkel, H; Smedema, JP | 1 |
| Cannon, CP; Kumar, A | 1 |
| Allen, C; Brudi, P; Henry, P; Johnson-Levonas, AO; Lim, ST; Lis, K; Massaad, R; Pomykaj, T; Reckless, JP; Vandormael, K | 1 |
| Birnbaum, Y; Lin, Y; Merla, R; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Tannen, RL; Weiner, MG; Xie, D | 1 |
| Gu, W; Kehl, F; Kersten, JR; Krolikowski, JG; Pagel, PS; Warltier, DC | 1 |
| Jay, RH | 1 |
| Kjekshus, J; Pedersen, TR | 1 |
| Durrington, PN | 1 |
| Reynolds, T; Wierzbicki, A | 1 |
| Armitage, J; Collins, R; Fatemian, M; Kearney, E; Keech, A; Lawson, A; Lyon, V; MacMahon, S; Mindell, J; Wallendszus, K | 1 |
| Day, AP; Stansbie, D | 1 |
| Shepherd, J | 1 |
| MacDonald, TM; MacFadyen, RJ; Mollon, I; Pringle, SD | 1 |
| Huttunen, J | 1 |
| Pederson, JP; Weintraub, WS | 1 |
| Aumont, MC; Seknadji, P | 1 |
| Faergeman, O; Kjekshus, J; Olsson, AG; Pedersen, TR; Pyŏrälä, K; Thorgeirsson, G | 1 |
| Bhatnagar, D | 1 |
| Berg, K; Cook, TJ; Faergeman, O; Kjekshus, J; Miettinen, TA; Musliner, TA; Olsson, AG; Pedersen, T; Pyörälä, K | 1 |
| Gutzwiller, F; Lüscher, TF; Szucs, TD | 1 |
| Kesäniemi, YA | 1 |
| Berg, K; Christophersen, B; Cook, TJ; Faergeman, O; Haghfelt, T; Kjekshus, J; Miettinen, T; Musliner, TA; Olsson, AG; Pedersen, TR; Pyörälä, K; Thorgeirsson, G; Tobert, JA; Wedel, H; Wilhelmsen, L | 1 |
| Butler, R; MacDonald, TM; Morris, AD; Newton, RW | 1 |
| Pedersen, TR | 2 |
| Furberg, CD | 1 |
| Kessler, KM | 1 |
| Hashimoto, T; Hosokawa, R; Linxue, L; Miki, S; Nohara, R; Sasayama, S; Tamaki, S; Tanaka, M | 1 |
| Faergeman, O; Gerdes, C; Gerdes, LU; Hansen, PS; Kervinen, K; Kesäniemi, YA; Klausen, IC; Savolainen, M | 1 |
| Arnheim, K | 1 |
| de Jongh, S; Kastelein, JJ; Lansberg, PJ; Trip, MD | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Clayton, A; Cummings, CE; Kirkpatrick, C; Kush, D; Liu, M; MacMahon, M; Robinson, PJ; Tobert, J; Tomiak, RH | 1 |
| Anderson, GM; Jackevicius, CA; Leiter, L; Tu, JV | 1 |
| Vita, JA; Winniford, M; Yeung, AC | 1 |
| Athyros, VG; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Asplund, K; Jonsson, N | 1 |
| Cook, T; Kjekshus , J; Pedersen, T; Pyörälä, K; Wedel, H; Wilhelmsen, L | 1 |
| Bilheimer, D; Blazing, MA; Braunwald, E; Califf, RM; De Lemos, JA; Dyke, CK | 1 |
| Auer, J; Eber, B | 1 |
| Farré, J; Gómez, J; López-Farré, A; Marcos-Alberca, P; Nuñez, A; Rico, L; Romero, J; Sánchez de Miguel, L | 1 |
| Jones, SP; Lefer, DJ; Trocha, SD | 1 |
| Collins, R | 1 |
| Böhm, M; Hamm, CW; Heeschen, C; Laufs, U; Snapinn, S; White, HD | 1 |
| Ravnskov, U | 1 |
| Brambilla, C; Brambilla, E; Devouassoux, G; Lantuejoul, S | 1 |
| de Boer, A; Fishman, PA; Heckbert, SR; Klungel, OH; Leufkens, HG; Psaty, BM; Sullivan, SD; Veenstra, DL | 1 |
23 review(s) available for simvastatin and Cardiovascular Stroke
| Article | Year |
|---|---|
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Triglycerides | 2018 |
Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Registries; Saphenous Vein; Simvastatin; Treatment Outcome; Young Adult | 2013 |
Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Biomarkers; Carotid Intima-Media Thickness; Child; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Mass Screening; Myocardial Infarction; Observational Studies as Topic; Preventive Health Services; Simvastatin; Stroke; United States | 2016 |
Interpretation of the evidence for the efficacy and safety of statin therapy.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Risk Assessment; Safety; Simvastatin; Stroke | 2016 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke | 2016 |
Change in serum lipids after acute coronary syndromes: secondary analysis of SPACE ROCKET study data and a comparative literature review.
Topics: Cholesterol; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Multicenter Studies as Topic; Myocardial Infarction; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2010 |
Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions.
Topics: Aspirin; Cilostazol; Dipyridamole; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Cardiovascular; Myocardial Infarction; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Simvastatin; Tetrazoles | 2010 |
Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management considerations.
Topics: Acute Kidney Injury; Aged, 80 and over; Coronary Artery Disease; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Myocardial Infarction; Renal Dialysis; Rhabdomyolysis; Simvastatin | 2013 |
[Lipid therapy in daily routine].
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Female; General Practice; Germany; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Practice Patterns, Physicians'; Prospective Studies; Simvastatin | 2012 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Choosing a drug from within a class.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Aspirin; Australia; Decision Making; Drug Costs; Drug Therapy, Combination; Drug Utilization; Drugs, Generic; Family Practice; Female; Humans; Hypertension; Indoles; Myocardial Infarction; Practice Patterns, Physicians'; Severity of Illness Index; Simvastatin | 2003 |
Statins and secondary prevention of coronary heart disease.
Topics: Adult; Aged; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin; Survival Analysis; Treatment Outcome | 2004 |
Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Safety of high-dose atorvastatin therapy.
Topics: Atorvastatin; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2005 |
[Thoughts about the results of the "IDEAL" study].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Follow-Up Studies; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2006 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
Statin therapy in clinical practice: new developments.
Topics: Angina Pectoris; Anticholesteremic Agents; Cholesterol; Enzyme Inhibitors; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Middle Aged; Myocardial Infarction; Simvastatin | 1995 |
[Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin | 1996 |
Serum triglycerides and clinical benefit in lipid-lowering trials.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Complications; Humans; Hypolipidemic Agents; Myocardial Infarction; Simvastatin | 1998 |
Statin trials and goals of cholesterol-lowering therapy after AMI.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Europe; Humans; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; United States | 1999 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
73 trial(s) available for simvastatin and Cardiovascular Stroke
| Article | Year |
|---|---|
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Simvastatin | 2021 |
Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction.
Topics: Anticholesteremic Agents; Clopidogrel; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Myocardial Infarction; Prospective Studies; Rosuvastatin Calcium; Scattering, Small Angle; Simvastatin; Ticagrelor; X-Ray Diffraction | 2022 |
Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Lipids; Male; Middle Aged; Myocardial Infarction; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction | 2021 |
Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Brain Ischemia; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Quality-Adjusted Life Years; Saudi Arabia; Simvastatin; Treatment Outcome | 2018 |
Prevention of post-operative complications by using a HMG-CoA reductase inhibitor in patients undergoing one-lung ventilation for non-cardiac surgery: study protocol for a randomised controlled trial.
Topics: Double-Blind Method; Elective Surgical Procedures; Esophagectomy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Myocardial Infarction; One-Lung Ventilation; Pneumonectomy; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome; Risk Factors; Simvastatin; Time Factors; Treatment Outcome; United Kingdom | 2018 |
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
Topics: Arterial Occlusive Diseases; Chemical and Drug Induced Liver Injury; Death, Sudden, Cardiac; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Myocardial Reperfusion; Niacin; Simvastatin; Stroke | 2013 |
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Management; Dyslipidemias; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Risk Factors; Risk Reduction Behavior; Simvastatin; Stroke | 2014 |
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Netherlands; Peripheral Arterial Disease; Prospective Studies; Pyrroles; Scandinavian and Nordic Countries; Simvastatin | 2015 |
[IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)].
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Simvastatin | 2014 |
Statin Recapture Therapy before Coronary Artery Bypass Grafting Trial: Rationale and study design of a multicenter, randomized, double-blinded controlled clinical trial.
Topics: Cardiotonic Agents; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Postoperative Complications; Premedication; Simvastatin; Stroke; Treatment Outcome | 2015 |
[Even lower values are even better!].
Topics: Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Myocardial Infarction; Risk Factors; Simvastatin; Stroke | 2015 |
Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cerebral Revascularization; Cholesterol, LDL; Comorbidity; Creatinine; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Electrocardiography; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Simvastatin; Treatment Outcome | 2015 |
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Simvastatin; Survival Rate; Time Factors; Treatment Outcome; United States | 2016 |
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Niacin; Proportional Hazards Models; Simvastatin; Treatment Outcome; Triglycerides | 2016 |
SLCO1B1 variants and statin-induced myopathy--a genomewide study.
Topics: Aged; Arterial Occlusive Diseases; Chromosomes, Human, Pair 12; Diabetes Mellitus; Female; Genetic Markers; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Organic Anion Transporters; Polymorphism, Single Nucleotide; Risk; Simvastatin | 2008 |
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; C-Reactive Protein; Cohort Studies; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metoprolol; Middle Aged; Myocardial Infarction; Propranolol; Simvastatin; Treatment Outcome | 2009 |
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Myocardial Infarction; Pyrroles; Simvastatin | 2009 |
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
Topics: Aged; Atorvastatin; Confounding Factors, Epidemiologic; Drug Prescriptions; Europe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2009 |
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
Topics: Atorvastatin; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2009 |
Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction.
Topics: Aged; Anticholesteremic Agents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Premedication; Simvastatin; Thrombin; Treatment Outcome | 2010 |
A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial.
Topics: Aged; Biomarkers; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Practice Guidelines as Topic; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United Kingdom | 2009 |
Intensive cholesterol-lowering therapy improves large artery elasticity in acute myocardial infarction patients.
Topics: Administration, Oral; Aged; Ankle; Arteries; Atherosclerosis; Biomarkers; Blood Pressure; Brachial Artery; Cholesterol; Cholesterol, LDL; Elasticity; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linear Models; Male; Middle Aged; Myocardial Infarction; Pulsatile Flow; Simvastatin; Treatment Outcome | 2009 |
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Atorvastatin; Canada; Cardiovascular Diseases; Confidence Intervals; Cost of Illness; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Markov Chains; Middle Aged; Myocardial Infarction; Probability; Pyrroles; Risk Assessment; Simvastatin; Survival Rate; Treatment Outcome | 2009 |
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Heart Arrest; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; Regression Analysis; Simvastatin | 2010 |
Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cholesterol, LDL; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Fluorobenzenes; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Myocardial Infarction; Neoplasm Proteins; Odds Ratio; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pyrimidines; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Sex Factors; Simvastatin; Stroke; Treatment Failure; Triglycerides | 2010 |
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)
Topics: Aged; Atorvastatin; Denmark; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Netherlands; Norway; Proportional Hazards Models; Prospective Studies; Pyrroles; Secondary Prevention; Simvastatin; Sweden; Treatment Outcome | 2010 |
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Simvastatin; Triglycerides; Young Adult | 2010 |
Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Cholesterol; Cholesterol, HDL; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation Mediators; Italy; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Secondary Prevention; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography | 2010 |
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study.
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Simvastatin; Stroke; United Kingdom | 2011 |
Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction.
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Brazil; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Myocardial Infarction; Nitric Oxide; Oxidative Stress; Prospective Studies; Simvastatin; Time Factors; Treatment Outcome; Vasodilation | 2011 |
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Simvastatin; Treatment Outcome | 2011 |
[Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial].
Topics: Angina, Unstable; Atorvastatin; Azetidines; C-Reactive Protein; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Sulfonamides; Treatment Outcome | 2011 |
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Neoplasms; Simvastatin; Stroke | 2011 |
Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Electrocardiography; Ezetimibe; Female; Follow-Up Studies; Heart Failure; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Prognosis; Simvastatin; Ventricular Dysfunction, Left | 2012 |
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke | 2013 |
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cause of Death; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Severity of Illness Index; Simvastatin; Stroke; United Kingdom | 2002 |
Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
Topics: Angina Pectoris; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Simvastatin; T-Lymphocytes | 2002 |
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Chemotherapy, Adjuvant; Coronary Artery Disease; Death, Sudden, Cardiac; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prospective Studies; Simvastatin | 2003 |
[Lowering cholesterol for prevention of myocardial infarct and stroke? MRC/BHF Heart Protection Study].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cerebral Infarction; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Long-Term Care; Male; Middle Aged; Myocardial Infarction; Risk Factors; Simvastatin; Survival Rate; Treatment Outcome | 2003 |
Comparison of two methods of presenting risk information to patients about the side effects of medicines.
Topics: Adult; Aged; Atorvastatin; Cardiac Surgical Procedures; Communication; Comprehension; Constipation; Drug Information Services; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Likelihood Functions; Male; Middle Aged; Myocardial Infarction; Pancreatitis; Patient Education as Topic; Physician-Patient Relations; Pyrroles; Risk Assessment; Simvastatin; Terminology as Topic | 2004 |
Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin.
Topics: Acute Disease; Aged; Angina Pectoris; C-Reactive Protein; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Simvastatin; Single-Blind Method; Syndrome | 2004 |
Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cell Adhesion; Cells, Cultured; Chemokine CX3CL1; Chemokines, CX3C; Chemotaxis; Cholesterol, LDL; Coronary Artery Disease; CX3C Chemokine Receptor 1; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Leukocytes, Mononuclear; Membrane Proteins; Myocardial Infarction; Pyrroles; Receptors, Chemokine; Simvastatin; Umbilical Veins | 2005 |
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk; Simvastatin | 2005 |
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Comorbidity; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Hospital Mortality; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Interleukin-6; Lipids; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Premedication; Preoperative Care; Prospective Studies; Pyrroles; Risk Assessment; Simvastatin; Systemic Inflammatory Response Syndrome; Troponin T | 2006 |
[The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Single-Blind Method; Treatment Outcome | 2006 |
Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Atherosclerosis; CD40 Ligand; Corn Oil; Double-Blind Method; Fatty Acids, Omega-3; Female; Humans; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Simvastatin | 2006 |
Gender difference in coronary events in relation to risk factors in Japanese hypercholesterolemic patients treated with low-dose simvastatin.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Asian People; Cholesterol, LDL; Coronary Disease; Death; Female; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Risk Factors; Sex Factors; Simvastatin | 2006 |
[Short term simvastatin use in patients with heart failure of ischemic origin. Changes of blood lipids, markers of inflammation and left ventricular function].
Topics: Aged; C-Reactive Protein; Cholesterol; Drug Administration Schedule; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Myocardial Contraction; Myocardial Infarction; Simvastatin; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Ventricular Function, Left | 2006 |
N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Chi-Square Distribution; Confidence Intervals; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Humans; Hypercholesterolemia; Linear Models; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Probability; Risk Assessment; Severity of Illness Index; Simvastatin; Stroke; Treatment Outcome | 2007 |
Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Renal Insufficiency, Chronic; Risk Factors; Scandinavian and Nordic Countries; Simvastatin | 2007 |
Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Simvastatin; Triglycerides | 2007 |
[Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Exercise; Exercise Therapy; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Lipids; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Simvastatin; Treatment Outcome; Triglycerides | 2007 |
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol; Dose-Response Relationship, Drug; Female; Folic Acid; Follow-Up Studies; Homocysteine; Humans; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Simvastatin; Survival Rate; Time Factors; Treatment Outcome; United Kingdom; Vitamin B 12; Vitamin B Complex | 2007 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Myocardial Infarction; Simvastatin; Treatment Outcome | 2008 |
Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Myocardial Infarction; Risk Factors; Scandinavian and Nordic Countries; Sex Factors; Simvastatin; Survival Rate | 1995 |
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Lipids; Lovastatin; Male; Middle Aged; Myocardial Infarction; Simvastatin; Treatment Outcome | 1994 |
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Topics: Adult; Aged; Angina Pectoris; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Myocardial Infarction; Risk Factors; Simvastatin; Survival Analysis | 1994 |
Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lipids; Liver Function Tests; Lovastatin; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Simvastatin; Survival Analysis; Survival Rate; Treatment Outcome | 1994 |
Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction.
Topics: Adult; Aged; Angina Pectoris; Anticholesteremic Agents; Double-Blind Method; Ethics, Medical; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Myocardial Infarction; Scandinavian and Nordic Countries; Simvastatin; Time Factors | 1993 |
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Lovastatin; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Placebos; Prognosis; Risk Factors; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; Time Factors; Triglycerides | 1997 |
Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)
Topics: Adult; Aged; Aging; Angina Pectoris; Anticholesteremic Agents; Cohort Studies; Female; Hospitalization; Humans; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Simvastatin; Survival Analysis | 1997 |
[Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions].
Topics: Adult; Aged; Angina Pectoris; Anticholesteremic Agents; Cost Control; Cost-Benefit Analysis; Female; Forecasting; Health Care Costs; Health Services Misuse; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; Switzerland | 1997 |
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, Dietary; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Regression Analysis; Risk Factors; Sensitivity and Specificity; Simvastatin; Triglycerides | 1998 |
Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography.
Topics: Angina Pectoris; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Simvastatin; Thallium; Tomography, Emission-Computed, Single-Photon | 2000 |
A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH).
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Factor Analysis, Statistical; Female; Folic Acid; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Placebos; Simvastatin; Triglycerides; Vitamin B 12 | 2000 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Simvastatin; Stroke | 2001 |
Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Diabetes Mellitus; Double-Blind Method; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Simvastatin; Smoking; Time Factors | 2001 |
The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.
Topics: Anticoagulants; Drug Therapy, Combination; Enoxaparin; Humans; Hypolipidemic Agents; Myocardial Infarction; Patient Selection; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Simvastatin; Tirofiban; Tyrosine | 2001 |
122 other study(ies) available for simvastatin and Cardiovascular Stroke
| Article | Year |
|---|---|
Down syndrome, severe psoriasis, and increased risk for cardiovascular events.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Down Syndrome; Fatal Outcome; Female; Heart Septal Defects; Humans; Hyperlipidemias; Hypolipidemic Agents; Interferon-gamma; Metoprolol; Middle Aged; Myocardial Infarction; Polycythemia; Psoriasis; Risk Factors; Severity of Illness Index; Simvastatin; Triamcinolone Acetonide | 2019 |
Treatment Patterns of Lipid-Lowering Therapy in Patients with Coronary Artery Disease Aged Above and Below 75 Years: A Retrospective Cross-Sectional Study of 1500 Patients in a Tertiary Care Referral Center in Germany.
Topics: Age Factors; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Cross-Sectional Studies; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Simvastatin; Tertiary Care Centers; Tertiary Healthcare | 2020 |
Is the decrease of triglyceride level after acute myocardial infarction within a month by the effect of combination therapy of Ezetimibe and Simvastatin.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Simvastatin; Treatment Outcome; Triglycerides | 2018 |
Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Drug Prescriptions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Prospective Studies; Registries; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; ST Elevation Myocardial Infarction; Tertiary Care Centers; Time Factors | 2019 |
Sevoflurane postconditioning is not mediated by ferritin accumulation and cannot be rescued by simvastatin in isolated streptozotocin-induced diabetic rat hearts.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Ferritins; Gene Expression Regulation; Heart; Iron; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Nitric Oxide; Rats; Sevoflurane; Simvastatin; Streptozocin | 2019 |
Simvastatin treatment inhibits hypoxia inducible factor 1-alpha-(HIF-1alpha)-prolyl-4-hydroxylase 3 (PHD-3) and increases angiogenesis after myocardial infarction in streptozotocin-induced diabetic rat.
Topics: Animals; Diabetes Mellitus, Experimental; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Myocardial Infarction; Neovascularization, Physiologic; Prolyl-Hydroxylase Inhibitors; Rats; Simvastatin; Streptozocin | 2013 |
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States | 2013 |
Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an observational retrospective study.
Topics: Aged; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Kaplan-Meier Estimate; Male; Matched-Pair Analysis; Middle Aged; Myocardial Infarction; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Simvastatin; Treatment Outcome | 2013 |
High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study.
Topics: Aged; Azetidines; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Female; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Myocardial Infarction; Population Surveillance; Retrospective Studies; Simvastatin; Survival Rate; Survivors; Time Factors; Treatment Outcome; United Kingdom | 2014 |
Lipid-lowering therapy and mortality post-MI: is it just about the LDL?
Topics: Azetidines; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Lipids; Male; Myocardial Infarction; Population Surveillance; Simvastatin; Survivors | 2014 |
Reduced apoptosis after acute myocardial infarction by simvastatin.
Topics: Acute Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Gene Expression Regulation; Heart Ventricles; Male; Myocardial Infarction; Organ Size; Proto-Oncogene Proteins c-bcl-2; Rabbits; Simvastatin | 2015 |
Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Thailand; Treatment Outcome | 2015 |
Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of TGF-β receptor III expression.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Survival; Cells, Cultured; Echocardiography; Fibrosis; Gene Knockdown Techniques; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MAP Kinase Signaling System; Mice; Myocardial Infarction; Proteoglycans; Receptors, Transforming Growth Factor beta; Simvastatin; Up-Regulation | 2015 |
Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.
Topics: Adenosine Triphosphatases; Animals; Atorvastatin; Blood Glucose; Cardiotonic Agents; Catalase; Cholesterol; Fatty Acids, Monounsaturated; Fluvastatin; Glutathione; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoproterenol; Male; Myocardial Infarction; Myocardium; Necrosis; Pravastatin; Rats, Wistar; Rosuvastatin Calcium; Simvastatin; Superoxide Dismutase; Triglycerides | 2015 |
Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men.
Topics: Cost-Benefit Analysis; Humans; Iran; Male; Markov Chains; Middle Aged; Models, Economic; Myocardial Infarction; Nonprescription Drugs; Quality-Adjusted Life Years; Simvastatin | 2015 |
PROVE-IT to IMPROVE-IT: Why LDL-C Goals Still Matter in Post-ACS Patients.
Topics: Acute Coronary Syndrome; Ezetimibe; Female; Humans; Male; Myocardial Infarction; Simvastatin | 2016 |
Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study.
Topics: Aged; Atorvastatin; Case-Control Studies; Comorbidity; Diabetes Mellitus; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Indoles; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pneumonia; Protective Factors; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Taiwan | 2016 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort Studies; Cost-Benefit Analysis; Humans; Hydrochlorothiazide; Losartan; Markov Chains; Middle Aged; Myocardial Infarction; Polypharmacy; Primary Prevention; Quality-Adjusted Life Years; Simvastatin; Stroke; United Kingdom | 2016 |
Starting the polypill: the use of a single age cut-off in males and females.
Topics: Adult; Age Factors; Aged; Cardiovascular Agents; Drug Combinations; Female; Humans; Hydrochlorothiazide; Losartan; Male; Middle Aged; Myocardial Infarction; Preventive Health Services; Simvastatin; State Medicine; Stroke; United Kingdom | 2017 |
Simvastatin ameliorates ventricular remodeling via the TGF‑β1 signaling pathway in rats following myocardial infarction.
Topics: Animals; Biomarkers; Disease Models, Animal; Heart Ventricles; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; MAP Kinase Kinase Kinases; Myocardial Infarction; Rats; Signal Transduction; Simvastatin; Smad3 Protein; Smad7 Protein; Transforming Growth Factor beta1; Ventricular Function, Left; Ventricular Remodeling | 2016 |
Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin; Stroke | 2017 |
Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Atorvastatin; Benzaldehydes; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Oximes; Phospholipase A2 Inhibitors; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Renal Insufficiency; Rosuvastatin Calcium; Secondary Prevention; Sex Factors; Simvastatin | 2017 |
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
Topics: Acute Coronary Syndrome; Aged; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Assessment; Secondary Prevention; Simvastatin; Treatment Outcome | 2017 |
Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients.
Topics: Aged; Cardiovascular Diseases; Drug Costs; Drugs, Generic; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Models, Theoretical; Myocardial Infarction; Rosuvastatin Calcium; Simvastatin; Stroke; Treatment Outcome | 2017 |
HMG-CoA reductase inhibitor regulates endothelial progenitor function through the phosphatidylinositol 3'-kinase/AKT signal transduction pathway.
Topics: AC133 Antigen; Animals; Antigens, CD; Antigens, CD34; Blotting, Western; Cells, Cultured; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Glycoproteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Peptides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; Simvastatin; Vascular Endothelial Growth Factor A | 2009 |
[Stable coronary heart disease--lessons from the COURAGE Study. With intensive drug therapy on the success track].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Combined Modality Therapy; Coronary Disease; Coronary Stenosis; Death, Sudden, Cardiac; Ezetimibe; Humans; Kaplan-Meier Estimate; Life Style; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.
Topics: Adult; Atorvastatin; Cohort Studies; Disease-Free Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
[Effects and potential mechanisms of short-term use of simvastatin on myocardial no-reflow after ischemia-reperfusion in rats].
Topics: Animals; Disease Models, Animal; Endothelium, Vascular; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Wistar; Simvastatin | 2008 |
Simvastatin reduces myocardial infarct size via increased nitric oxide production in normocholesterolemic rabbits.
Topics: Animals; Cholesterol; Coronary Vessels; Enzyme Inhibitors; Heart; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; NG-Nitroarginine Methyl Ester; Nitric Oxide; Organ Size; Rabbits; Simvastatin | 2009 |
Myocardial infarction in a 72-year-old woman with low LDL-C and increased hsCRP: implications for statin therapy.
Topics: Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Female; Humans; Myocardial Infarction; Predictive Value of Tests; Risk; Severity of Illness Index; Simvastatin | 2009 |
Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarction.
Topics: Animals; Apoptosis; Caspase 3; Cell Membrane; Cell Movement; Disease Models, Animal; Enzyme Inhibitors; Group II Phospholipases A2; Heart Function Tests; Immunohistochemistry; Macrophages; Myocardial Infarction; Myocytes, Cardiac; Neutrophils; Rats; Rats, Wistar; Simvastatin; Solubility | 2009 |
Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal.
Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Simvastatin; Time Factors; Up-Regulation | 2009 |
Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atherectomy; Catheter Ablation; Clopidogrel; Coronary Artery Bypass; Diabetes Mellitus; Drug Therapy, Combination; Female; Health Care Costs; Hospital Costs; Humans; Male; Medical Record Linkage; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Proportional Hazards Models; Registries; Risk Factors; Simvastatin; Sweden; Ticlopidine; Treatment Outcome | 2010 |
Simvastatin alleviates myocardial contractile dysfunction and lethal ischemic injury in rat heart independent of cholesterol-lowering effects.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Cholesterol; Diabetes Mellitus, Experimental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Contraction; Myocardial Infarction; Myocardial Ischemia; Myocardium; Perfusion; Rats; Rats, Wistar; Recovery of Function; Simvastatin; Ventricular Pressure | 2009 |
Factors associated with recurrent coronary events among patients with cardiovascular disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Risk Factors; Secondary Prevention; Simvastatin | 2009 |
Rosuvastatin for cardiovascular prevention: too many uncertainties.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; Uncertainty | 2009 |
Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts.
Topics: Animals; Apoptosis; Cell Differentiation; Cell Survival; Combined Modality Therapy; Cytokines; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Muscle Development; Myocardial Infarction; Myocardium; Oxidative Stress; Simvastatin; Swine; Swine, Miniature | 2009 |
In rats with myocardial infarction, interference by simvastatin with the TLR4 signal pathway attenuates ventricular remodelling.
Topics: Animals; Anticholesteremic Agents; Dilatation, Pathologic; Endothelium, Vascular; HSP70 Heat-Shock Proteins; Interleukin-6; Male; Myocardial Infarction; Rats; Simvastatin; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2009 |
Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin.
Topics: Animals; Aspirin; CREB-Binding Protein; Dipyridamole; Dose-Response Relationship, Drug; Drug Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Simvastatin | 2010 |
Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.
Topics: Aged; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Statistics as Topic | 2011 |
[On the current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Financing, Personal; Fluorobenzenes; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Myocardial Infarction; National Health Programs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2010 |
Effect of simvastatin on collagen I deposition in non-infarcted myocardium: role of NF-κB and osteopontin.
Topics: Animals; Collagen Type I; Fibrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardium; NF-kappa B; NF-kappa B p50 Subunit; Osteopontin; Rats; Rats, Sprague-Dawley; RNA, Messenger; Simvastatin; Ventricular Function, Left | 2010 |
The effects of simvastatin on angiogenesis: studied by an original model of atherosclerosis and acute myocardial infarction in rabbit.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Coronary Angiography; Disease Models, Animal; Heart Function Tests; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Lipids; Male; Myocardial Infarction; Neovascularization, Pathologic; Rabbits; Simvastatin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Statins have an early antiplatelet effect in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Arachidonic Acid; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Pravastatin; Simvastatin | 2011 |
CRP: star trekking the galaxy of risk markers.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Revascularization; Randomized Controlled Trials as Topic; Simvastatin; Stroke | 2011 |
Half-dose ezetimibe add-on to statin therapy is effective in improving resistant hyperlipidaemia in Asian patients with ischaemic heart disease.
Topics: Aged; Asia; Azetidines; Cholesterol; Cohort Studies; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Simvastatin; Treatment Outcome | 2011 |
Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiotonic Agents; Coronary Circulation; Disease Models, Animal; Drug Therapy, Combination; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Simvastatin | 2012 |
Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress.
Topics: Animals; Anticholesteremic Agents; Disease Models, Animal; Hypercholesterolemia; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Rabbits; Simvastatin | 2012 |
Phosphorylation of endothelial NOS contributes to simvastatin protection against myocardial no-reflow and infarction in reperfused swine hearts: partially via the PKA signaling pathway.
Topics: Animals; Anticholesteremic Agents; Creatine Kinase; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Heart; Hemodynamics; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase Type III; Phosphorylation; Signal Transduction; Simvastatin; Swine; Swine, Miniature | 2012 |
Simvastatin attenuates sympathetic hyperinnervation to prevent atrial fibrillation during the postmyocardial infarction remodeling process.
Topics: Animals; Atrial Fibrillation; Hypolipidemic Agents; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Simvastatin; Sympathetic Nervous System; Treatment Outcome | 2012 |
Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Chi-Square Distribution; Comorbidity; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Polypharmacy; Pravastatin; Propensity Score; Proportional Hazards Models; Pyrroles; Registries; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin; Time Factors; Treatment Outcome | 2014 |
Paracetamol and simvastatin: a potential interaction resulting in hepatotoxicity.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Coronary Artery Bypass; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Jaundice; Liver; Myocardial Infarction; Nausea; Simvastatin; Vomiting | 2012 |
Pleiotropic effects of simvastatin are associated with mitigation of apoptotic component of cell death upon lethal myocardial reperfusion-induced injury.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Death; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Wistar; Reperfusion Injury; Simvastatin | 2012 |
Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction.
Topics: Animals; Arteries; Cattle; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Heart Failure; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Organ Culture Techniques; Rats; Rats, Sprague-Dawley; Reference Values; Simvastatin; Time Factors; Vasodilation; Vasomotor System | 2002 |
Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Health Services for the Aged; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; New York; Peripheral Vascular Diseases; Pravastatin; Prospective Studies; Simvastatin; Treatment Outcome; Triglycerides | 2002 |
[Dangerous plaque often symptom-free. ACE inhibitors prevent rupture].
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cerebral Infarction; Clinical Trials as Topic; Humans; Myocardial Infarction; Ramipril; Risk Factors; Simvastatin | 2002 |
MRC/BHF Heart Protection Study.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Myocardial Infarction; Simvastatin; Treatment Outcome | 2002 |
Benefits of simvastin in cholesterol lowering.
Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Stroke; United Kingdom | 2003 |
Statins in threatened stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Simvastatin; Stroke; Survival Rate; Treatment Outcome | 2003 |
Effect of statins on mortality and cardiovascular events in elderly high-risk persons.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cause of Death; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Severity of Illness Index; Simvastatin; Stroke; United Kingdom | 2003 |
Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat.
Topics: Animals; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Simvastatin; Transcription Factors | 2003 |
[Preventing infarct by lowering LDL. Is 100 the upper limit for every diabetic patient?].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Diabetic Angiopathies; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Myocardial Infarction; Reference Values; Risk Factors; Simvastatin; Survival Rate | 2003 |
A cholesterol drug protects some people with diabetes.
Topics: Anticholesteremic Agents; Diabetic Angiopathies; Humans; Myocardial Infarction; Simvastatin; Stroke | 2003 |
Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels.
Topics: Animals; Anti-Arrhythmia Agents; ATP-Binding Cassette Transporters; Collateral Circulation; Disease Models, Animal; Drug Therapy, Combination; Glyburide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Models, Cardiovascular; Myocardial Infarction; Myocardial Reperfusion Injury; Potassium Channels; Rats; Rats, Sprague-Dawley; Simvastatin; Statistics as Topic | 2004 |
Updated guidelines support even lower cholesterol levels for at-risk patients.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Factors; Risk Reduction Behavior; Simvastatin; Triglycerides; United States | 2004 |
Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway.
Topics: Androstadienes; Animals; Cholesterol; Coronary Stenosis; Drug Administration Schedule; Injections, Intravenous; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; Simvastatin; Time Factors; Wortmannin | 2004 |
Doubling Zocor dose fails to double its benefit.
Topics: Anticholesteremic Agents; Humans; Myocardial Infarction; Secondary Prevention; Simvastatin; Treatment Failure | 2004 |
Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; C-Reactive Protein; Coronary Angiography; Female; Fibrinogen; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Prognosis; Prospective Studies; Simvastatin; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Left | 2005 |
Simvastatin over the counter.
Topics: Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Nonprescription Drugs; Safety; Self Medication; Simvastatin | 2005 |
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis | 2005 |
Plaque regression--a new target for antiatherosclerotic therapy.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Premedication; Pyrroles; Radiography; Remission Induction; Risk Reduction Behavior; Simvastatin; Ultrasonography | 2005 |
Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction.
Topics: Animals; Blotting, Western; Body Weight; Collagen Type I; Cytokines; Disease Models, Animal; Echocardiography; Female; Gene Expression; Heart; Hemodynamics; Immunohistochemistry; Lipids; Myocardial Infarction; Myocardium; Organ Size; Polymerase Chain Reaction; Rats; Rats, Wistar; Simvastatin; Ventricular Remodeling | 2005 |
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size.
Topics: Animals; Cells, Cultured; Clinical Trials as Topic; Endothelium, Vascular; Exocytosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Myocardial Infarction; N-Ethylmaleimide-Sensitive Proteins; Neutrophil Infiltration; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Simvastatin; Vesicular Transport Proteins; Weibel-Palade Bodies | 2005 |
Statin use after acute myocardial infarction: a nationwide study in Denmark.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Atorvastatin; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Population Surveillance; Pravastatin; Pyrroles; Registries; Sex Distribution; Simvastatin | 2005 |
Wider role seen for "remarkable" statins. Study suggests that benefits extend even to those with "normal" cholesterol levels.
Topics: Anticholesteremic Agents; Diabetic Angiopathies; Female; Humans; Male; Myocardial Infarction; Simvastatin; Stroke; Treatment Refusal | 2002 |
Acute myocardial infarction in a patient with severe unrecognized mitral stenosis.
Topics: Analgesics; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Diuretics; Echocardiography, Transesophageal; Electrocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Hydrochlorothiazide; Metoprolol; Middle Aged; Mitral Valve Stenosis; Myocardial Infarction; Nadroparin; Simvastatin; Time Factors; Treatment Outcome | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardium; Pilot Projects; Simvastatin; Troponin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATP channel.
Topics: Animals; Antigens, CD; Cadherins; Cardiac Output; Cholesterol; Disease Models, Animal; Electrocardiography; Hydroxymethylglutaryl-CoA Reductase Inhibitors; KATP Channels; Myocardial Infarction; Potassium Channels, Inwardly Rectifying; Simvastatin; Swine; Swine, Miniature; Ventricular Function, Left | 2007 |
Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure.
Topics: Animals; Gene Expression Regulation, Enzymologic; Heart Failure; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocardial Infarction; Nitric Oxide Synthase Type III; Pulmonary Edema; Severity of Illness Index; Simvastatin; Survival Rate; Ventricular Dysfunction, Left | 2006 |
Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel.
Topics: Animals; Antigens, CD; Cadherins; Cholesterol; Coronary Circulation; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Potassium Channels; Simvastatin; Swine; Swine, Miniature | 2006 |
Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Carbazoles; Carvedilol; Death; Disease-Free Survival; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Propanolamines; Retrospective Studies; Simvastatin; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2006 |
Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Diet; Echocardiography; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Models, Animal; Myocardial Infarction; Nitric Oxide Synthase Type III; Rabbits; rac1 GTP-Binding Protein; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simvastatin; Ventricular Dysfunction, Left | 2006 |
Effects of Tribuli saponins on ventricular remodeling after myocardial infarction in hyperlipidemic rats.
Topics: Animals; Cardiac Volume; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Ventricles; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Myocardial Infarction; Plant Extracts; Random Allocation; Rats; Rats, Sprague-Dawley; Saponins; Simvastatin; Stroke Volume; Tribulus; Ultrasonography; Ventricular Remodeling | 2007 |
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
Topics: Aged; Atorvastatin; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Substance Withdrawal Syndrome; Troponin T; Vascular Surgical Procedures | 2007 |
Myocardial infarcts in a patient with a single right sided coronary ostium and interarterial course of the circumflex artery: the role of multi-modality imaging.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Bisoprolol; Coronary Angiography; Coronary Vessel Anomalies; Coronary Vessels; Female; Humans; Magnetic Resonance Angiography; Middle Aged; Myocardial Infarction; Perindopril; Platelet Aggregation Inhibitors; Simvastatin; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2009 |
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Up-Regulation | 2008 |
Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding.
Topics: Adult; Aged; Confounding Factors, Epidemiologic; Coronary Disease; Data Interpretation, Statistical; Databases, Factual; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medical Records Systems, Computerized; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Primary Health Care; Randomized Controlled Trials as Topic; Simvastatin; Survival Analysis | 2008 |
Simvastatin restores ischemic preconditioning in the presence of hyperglycemia through a nitric oxide-mediated mechanism.
Topics: Animals; Blood Glucose; Dogs; Female; Hyperglycemia; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Nitric Oxide; Simvastatin | 2008 |
Lowering patients' cholesterol. Excluding patients from trials increases uncertainty.
Topics: Anticholesteremic Agents; Cholesterol; Humans; Lovastatin; Myocardial Infarction; Research Design; Simvastatin | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1995 |
Treatment of myocardial infarction and angina. Advice on reducing cholesterol should be included.
Topics: Angina Pectoris; Anticholesteremic Agents; Cholesterol; Humans; Lovastatin; Myocardial Infarction; Simvastatin | 1995 |
Biochemical diagnosis of myocardial infarction? Cardiac enzymes or caveat emptor.
Topics: Creatine Kinase; Diagnosis, Differential; Humans; Lovastatin; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Simvastatin | 1994 |
Implementation of the 4S study in first myocardial infarction.
Topics: Anticholesteremic Agents; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Simvastatin | 1996 |
[The cholesterol hypothesis has been proved true at last].
Topics: Adult; Aged; Angina Pectoris; Anticholesteremic Agents; Cholesterol; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Myocardial Infarction; Simvastatin | 1995 |
Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Disease; Death, Sudden, Cardiac; Humans; Lovastatin; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence; Scandinavian and Nordic Countries; Simvastatin; Survival Analysis | 1996 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Humans; Lipids; Lovastatin; Male; Myocardial Infarction; Pravastatin; Simvastatin | 1997 |
Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Cross-Cultural Comparison; Drug Utilization; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; United States | 1998 |
Coronary artery disease: the Scandinavian Simvastatin Survival Study experience.
Topics: Angina Pectoris; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Hyperlipidemias; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin | 1998 |
Natural statins and stroke risk.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Humans; Myocardial Infarction; Pravastatin; Simvastatin | 1999 |
Relative risk reduction in trial results.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Humans; Myocardial Infarction; Risk Factors; Scandinavian and Nordic Countries; Scotland; Simvastatin; Survival Rate | 1999 |
The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study.
Topics: Adult; Aged; Alleles; Apolipoprotein E4; Apolipoproteins E; Female; Follow-Up Studies; Genotype; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Prognosis; Proportional Hazards Models; Simvastatin | 2000 |
[Coronary heart disease: grave deficiencies in secondary prevention. Almost no one is concerned with blood lipids].
Topics: Aged; Anticholesteremic Agents; Combined Modality Therapy; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Simvastatin; Survival Rate | 2000 |
[Familial hypercholesterolemia: recognition and prevention of cardiac complications at a young age].
Topics: Adult; Age Factors; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Arcus Senilis; Cholesterol, HDL; Cholesterol, LDL; Diagnosis, Differential; Diet, Fat-Restricted; Female; Humans; Hyperlipoproteinemia Type II; Male; Myocardial Infarction; Simvastatin | 2000 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |
Use of the statins in patients after acute myocardial infarction: does evidence change practice?
Topics: Aged; Clinical Trials as Topic; Drug Utilization; Evidence-Based Medicine; Female; Humans; Hypolipidemic Agents; Lipids; Male; Medicine; Myocardial Infarction; Practice Patterns, Physicians'; Pravastatin; Publishing; Simvastatin; Specialization; Survival Rate | 2001 |
Coronary artery reactivity after treatment with simvastatin.
Topics: Amlodipine; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Female; Humans; Male; Myocardial Infarction; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Simvastatin; Survival Rate; Treatment Outcome | 2001 |
[Secondary prevention in myocardial infarct patients. Early treatment with statins].
Topics: Combined Modality Therapy; Humans; Hypolipidemic Agents; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Recurrence; Simvastatin; Survival Rate | 2000 |
Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study.
Topics: Acute Disease; Adult; Age Distribution; Aged; Case-Control Studies; Cerebral Hemorrhage; Comorbidity; Diabetes Mellitus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pilot Projects; Prognosis; Retrospective Studies; Secondary Prevention; Sex Distribution; Simvastatin; Stroke; Sweden; Treatment Outcome | 2001 |
[Hypercholesterolemia in high risk patients. Targeting low goal values].
Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypercholesterolemia; Myocardial Infarction; Simvastatin; Survival Rate | 2001 |
[Simvastatin after myocardial infarct. Losing no time].
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Myocardial Infarction; Simvastatin; Survival Analysis | 2001 |
Expression of an endothelial-type nitric oxide synthase isoform in human neutrophils: modification by tumor necrosis factor-alpha and during acute myocardial infarction.
Topics: Adult; Aged; Blotting, Northern; Down-Regulation; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Neutrophils; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Simvastatin; Tumor Necrosis Factor-alpha | 2001 |
Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion.
Topics: Animals; Anticholesteremic Agents; Hemodynamics; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Premedication; Simvastatin; Ultrasonography; Ventricular Dysfunction, Left | 2001 |
Heart protection study finds simvastatin reduces vascular risk in a wide range of high-risk patients.
Topics: Anticholesteremic Agents; Controlled Clinical Trials as Topic; England; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Simvastatin; Stroke | 2002 |
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
Topics: Acute Disease; Cholesterol; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Pravastatin; Proportional Hazards Models; Risk Factors; Simvastatin; Substance Withdrawal Syndrome; Survival Rate; Treatment Outcome; Troponin; United States | 2002 |
Statins as the new aspirin. Conclusions from the heart protection study were premature.
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Myocardial Infarction; Risk Factors; Simvastatin | 2002 |
Statin-induced fibrotic nonspecific interstitial pneumonia.
Topics: Adrenal Cortex Hormones; Biopsy, Needle; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypolipidemic Agents; Immunohistochemistry; Lung Diseases, Interstitial; Male; Middle Aged; Myocardial Infarction; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Simvastatin; Tomography, X-Ray Computed | 2002 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2002 |